[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 8, 1995

Possible Ocular Adverse Effects Associated With Leuprolide Injections

Author Affiliations

Oregon Health Sciences University Portland
World Health Organization Uppsala, Sweden

JAMA. 1995;273(10):773-774. doi:10.1001/jama.1995.03520340027021

To the Editor.  —Leuprolide acetate (Lupron Depo, Lupron Injection, TAP Pharmaceuticals Inc, Deerfield, Ill) is a gonadotropin-releasing hormone used to control endometriosis or advanced prostatic cancer. To our knowledge, this is the first overview of possible adverse ocular events occurring in patients receiving this drug. Cases were received from TAP Pharmaceuticals Inc, the World Health Organization Collaborating Center for International Drug Monitoring, Uppsala, Sweden (which instigated this review), and the National Registry of Drug-Induced Ocular Side Effects, Casey Eye Institute, Portland, Ore.The most common adverse ocular event possibly associated with leuprolide acetate is blurred vision, with or without headaches and/or dizziness (Table). This may occur after each injection or as late as the sixth injection, as in one patient. Transitory blurred vision may occur shortly after the injection, usually lasting 1 to 2 hours, but in rare instances may continue for 2 to 3 weeks. This may be a